We are the best strategic partner to lead innovative drugs
from EU approval to national P&R and Market Access in Spain,
specialised in oncology, orphan drugs and Advanced Therapies (ATMPs)

We are the best strategic partner to lead
innovative drugs from EU approval
to national P&R and Market Access in Spain,
specialised in oncology, orphan drugs
and Advanced Therapies (ATMPs)

neo2020-09-10T10:26:51+00:00

WHAT WE DO

We offer strategic support to companies during the drugs’ full lifecycle: from the regulatory process, including the Therapeutic Positioning Report (TPR) development to P&R submission, negotiation and approval, and Market Access at regional and hospital level. We do so by collaborating with relevant stakeholders, scientific societies and patients associations to ensure a successful Pricing and Market Access for innovative drugs in Spain.

OMAKASE LEADERSHIP TEAM

 ALICIA GIL
ALICIA GILPARTNER & CEO
XAVIER BADIA
XAVIER BADIAPARTNER & CEO

PUBLICATIONS

NEWS & EVENTS

The September 2020 summary of P&R decisions from the Spanish Interministerial Medicinal Products Pricing Committee (CIPM) is now translated and available to download in English.

October 29th, 2020|

Adding up methodologies like GENESIS and Multi Criteria Decision Analysis (MCDA), a way to explore in the near future to improve drugs evaluation in Spain.

October 22nd, 2020|

Yesterday, in the 65th SEFH virtual Congress, a panel of 3 experts from Orphar-SEFH group and Dr. Badia from Omakase Consulting shared their experiences about Horizon Scanning reports talking about how to develop it and use it for anticipating new drugs coming to Spain. 

October 21st, 2020|

GET IN TOUCH

CONTACT INFO

BARCELONA & MADRID OFFICES

Telephone: +34 674614704 | +34 931890969

E-mail: administracion@omakaseconsulting.com

APPLY FOR A JOB

Please send your CV to: administracion@omakaseconsulting.com

Follow Us On Social Media!

This website uses cookies so that you have the best user experience. If you continue browsing you are giving your consent for the acceptance of the aforementioned cookies and the acceptance of our cookies policy, Click on the link for more information. ACEPTAR

Aviso de cookies